anti-gprc5d monoclonal antibody sar446523
Generic: Anti-GPRC5D Monoclonal Antibody SAR446523
anti-gprc5d monoclonal antibody sar446523: 1 clinical trial tracked.
anti-gprc5d monoclonal antibody sar446523 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-gprc5d monoclonal antibody sar446523, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
A First-in-human, Open-label, Phase 1 Study to Evaluate the Safety, Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of Subcutaneous SAR446523, an Anti-GPRC5D ADCC-enhanced Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma
Primary endpoint: Incidence of Dose Limiting Toxicities (DLTs)- Dose escalation (Part A)
InterventionalRandomizedopen87 targetStarted 2024-10Completion 2031-0519 sites · Australia, Canada, France, Israel…Sanofi